File:Cyclophosphamide-2000-results.png

Summary[edit | edit source]

Title: (or description)[edit | edit source]

Cyclophosphamide ME/CFS trial results extended follow-up.
Key:
(A): SF-36 Physical Function (SF-36-PF); (B) percent function level; (C): mean steps per 24hrs; CI: confidence intervals.
Numbers of patients at the different time points through follow-up are shown below the graphs.^[1]

Author: (or citation)[edit | edit source]

Rekeland IG, Fosså A, Lande A, Ktoridou-Valen I, Sørland K, Holsen M, Tronstad KJ, Risa K, Alme K, Viken MK, Lie BA, Dahl O, Mella O, Fluge Ø (2020). "Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study". Front. Med. 7: 162. doi:10.3389/fmed.2020.00162.

Source: (e.g. internet address)[edit | edit source]

doi 10.3389/fmed.2020.00162 Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study

Other information:[edit | edit source]

See also[edit | edit source]

• CycloME
• Cyclophosphamide

Licensing[edit | edit source]

	This file is licensed under the Creative Commons Attribution 4.0 International license.
	You are free: to share – to copy, distribute and transmit the work to remix – to adapt the work Under the following conditions: attribution – You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. https://creativecommons.org/licenses/by/4.0 CC BY 4.0 Creative Commons Attribution 4.0 truetrue